Jeffrey S. Borer, M.D., is Professor of Medicine, Cell Biology, Radiology and Surgery at the State University of New York Downstate Medical Center. For 4 years, he served as Chairman, Department of Medicine, at SUNY Downstate, an administrative position he relinquished in 2013, but continues to serve as Chief, Division of Cardiovascular Medicine, and Director of two research institutes at Downstate. Dr. Borer received a BA from Harvard, a M.D. from Cornell, trained at the Massachusetts General Hospital, spent 7 years in the Cardiology Branch, NHLBI, and a year at Guy’s Hospital (London) as Senior Fullbright Hays Scholar and Glorney-Raisbeck Fellow in the Medical Sciences, completing the first clinical demonstration of nitroglycerin’s utility in acute MI following his several years of preclinical studies at NIH. Upon returning to the NIH, he developed stress radionuclide cineangiography, enabling the first non-invasive assessment of cardiac function with exercise. He returned to Cornell for 30 years as Gladys and Roland Harriman Professor of Cardiovascular Medicine and Chief, Division of Cardiovascular Pathophysiology. At Cornell and now at Downstate, he performs clinical service, teaching and research, the latter primarily developing prognosticators for regurgitant valve diseases, exploring the cellular/molecular biology of valve diseases, and assessing the effects of heart rate modification on clinical outcomes, with trials in coronary artery disease and heart failure. He has been an Advisor to the USFDA for 37 years, chaired the CardioRenal Drugs Advisory Committee for 3 terms and the Circulatory Devices Advisory Panel for one term, was a life sciences Advisor to NASA for 24 years, has served as officer/board member of several national professional societies (currently President, Heart Valve Society of America), has published almost 450 scientific papers and 6 books, has participated in various roles in numerous clinical trials of therapies, is editor-in-chief of the journal, Cardiology, and has received several awards and other recognitions for his work. His research has been supported by NIH, AHA and, for many years, by several large private foundations.
Massachusetts General Hospital, Residency in Internal Medicine
National Institutes of Health, National Heart, Lung, and Blood Institute (Residency)
Harvard University (Bachelor’s)
American College of Cardiology
American Heart Association
The American Society for Clinical Investigation
Heart Failure Society of America
International Academy of Cardiovascular Sciences
Association of University Cardiologists
European Society of Cardiology
New York Academy of Medicine
New York Cardiological Society
Awards and Publications
Major Awards, from many, below:
Lifetime Achievement Award, Heart Valve Society of America and Society for Heart Valves Disease (London), 2014
“Legend of Cardiology” Award, 10th Annual Global Summit on Complex Cardiovascular Catheter Therapeutics, 2014
Diversity in Cardiology Award, Assoc of Black Cardiologists, 2013
Award for Outstanding Contribution to Preventive Cardiology in Israel, Israel National Heart to Heart Assoc, 1992
Transforming Lives Through Research Award, SUNY Downstate Med Ctr, 2009
Distinguished Fellowship Award for Profound Contributions to Cardiovascular Medicine, Internat Academy of Cardiology 2005
Hans-Peter Krayenbuehl Memorial Award for Distinguished Research in Cardiac Function, Internat Academy of Cardiology, 2002
USFDA Service Award, 2004
Public Service Medal, National Aeronautics and Space Administration (NASA), 1999
Special Citation, NASA, for sustained contributions to US-Russia mission, 1997
Special Award for outstanding contributions to cardiology and cardiac surgery, Assoc of Thoracic and Cardiovasc Surgeons of India, 1985a
Established Investigator, American Heart Association, 1979-1984
Senior Fulbright-Hays Scholar, 1974-1975
Publications: 15 top from among 450 articles and 6 books:
1. Borer, et al.Reduction in myocardial ischemia with nitroglycerin....during acute myocardial infarction.... New Engl J Medicine 1975;293:1008-1012
2. Borer, et al. Real-time radionuclide cineangiography in the noninvasive evaluation of....left ventricular function....during exercise in....coronary artery disease. New Engl J Medicine 1977;296:839-844.
3. Borer, et al. Exercise-induced left ventricular dysfunction in....aortic regurgitation...by radionuclide cineangiography. American J Cardiol 1979;42:351-357.
4. Borer, et al. Right ventricular function in severe...mitral insufficiency. European J Cardiol 1991;12 (Supplement B):22-25
5. Borer, et al. Natural history of left ventricular performance at rest and during exercise after aortic valve replacement for aortic regurgitation. Circulation 1991;84(Suppl III):III-133-III-139.
6. Borer, et al. Prediction of indications for valve replacement among asymptomatic or minimally symptomatic patients with chronic aortic regurgitation and normal left ventricular performance. Circulation 1998; 97:525-534.
7. Borer, et al. Myocardial fibrosis in chronic aortic regurgitation: molecular and cellular response to volume overload. Circulation 2002;105:1837-1842.
8. Borer, et al. Anti-anginal and anti-ischemic effects of ivabradine....in stable angina: a randomized, double-blinded, multicentered, placebo-controlled trial. Circulation 2003;107:817-823.
9. Borer, et al. . Contemporary approach to aortic and mitral regurgitation. Circulation 2003;108:2432-2438.
10. Borer, et al.Development of cardiovascular drugs: the U.S. regulatory milieu from the perspective of a participating nonregulator. J Amer Coll Cardiol, 2004;44:2285-2292.
11. Borer, et al.Assessment of cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. European Heart J 2007;28:1904-1909.
12. Borer, et al. Reduction in hospitalisation for worsening of heart failure with ivabradine in patients with chronic systolic heart failure in the SHIFT trial. European Heart J 2012; 33:2813-2820
13. Borer JS. Mitral regurgitation: has another magic bullet bitten the dust? Circulation Heart Failure 2013;6;624-626
14. Borer JS. Drug-induced valve disease and considerations of benefit versus risk. European Heart Journal 2013; 34: 3535-3537
15. Borer, et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure/left ventricular dysfunction in the SHIFT trial. American J Cardiol 2014; 113: 497-503
16. Heart Valve Society of America (Founding President)